| Bioactivity | Tamtuvetmab (AT-005) is a caninised blontuvetmab against CD52. Tamtuvetmab increases progression-free survival (PFS), exhibits in vivo efficacy in dogs with naïve T-cell lymphoma (LSA). Tamtuvetmab has been approved by veterinary[1][2]. |
| Target | CD52 |
| In Vivo | Tamtuvetmab (5 mg/mL, 7.5-30 mL; i.v.; 15-30 min) has in vivo efficacy in dogs with naïve T-cell lymphoma (LSA), but resulting in vomiting, weight loss, diarrhoea, lethargy, decreased appetite and anorexia[1]. Animal Model: |
| Name | Tamtuvetmab |
| CAS | 1608122-71-9 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Musser ML, et al. Randomised trial evaluating chemotherapy alone or chemotherapy and a novel monoclonal antibody for canine T-cell lymphoma: A multicentre US study. Vet Rec Open. 2022 Nov 1;9(1):e49. [2]. Rhodes L. Changing innovation into a registered product: From concept to regulatory approval. Theriogenology. 2018 May;112:75-81. |